Spero Therapeutics news centers on its work as a clinical-stage biopharmaceutical company focused on immunology and inflammation. Company updates often address SP001, its third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease.
Other important Spero news relates to Utebzi, the Spero-developed oral antibiotic licensed to GSK for most territories and to Meiji for certain Asian territories. Updates may involve FDA-related disclosures, partner-linked commercialization rights, milestone and royalty arrangements, and financing backed by portions of future Utebzi payments.
Spero also issues news on quarterly operating results, business updates, healthcare conference presentations, executive and clinical leadership appointments, and inducement equity grants under Nasdaq listing rules. These categories reflect both its drug-development pipeline and its public-company reporting obligations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 1, 2020, the grant of stock options totaling 29,500 shares to four new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $11.82 per share, vest over four years, incentivizing employee retention. This grant aligns with Nasdaq Listing Rule 5635(c)(4), allowing equity awards to non-employees as a recruitment tool. Spero focuses on treating multi-drug resistant infections and rare diseases, advancing key candidates like tebipenem HBr for MDR infections and SPR720 for a rare disease associated with NTM.
Spero Therapeutics (Nasdaq: SPRO) has completed enrollment in its pivotal Phase 3 ADAPT-PO trial for tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI) in approximately 1,370 patients. Top-line results are expected in Q3 2020. The company also plans to initiate a Phase 2a trial for SPR720, targeting non-tuberculous mycobacterial disease. Financially, Spero reported a Q1 2020 net loss of $23.3 million, significantly higher than the $5.1 million loss in Q1 2019. Total revenue dropped to $1.7 million from $7.7 million in the prior year due to reduced funding and collaboration revenue.
Spero Therapeutics (Nasdaq: SPRO) announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, for tebipenem HBr, targeting complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). This milestone involves over 1,370 subjects and aims to compare an oral regimen of tebipenem HBr against standard intravenous treatment. The company expects to report topline results in Q3 2020, emphasizing the unmet need for effective oral therapies to reduce hospitalizations caused by drug-resistant infections.
Summary not available.